Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Abingworth Bioventures VII (ABV VII)

Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in 170 life science companies, leading to 44 M&As and 69 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. *

 

Period Start 2018-07-09 fund closing
  Group Abingworth (Group)
Products Industry venture capital
  Industry 2 LIFE SCIENCES
Persons Person Haines, Timothy (Tim) (Abingworth 201507– Managing Partner joined 2005 before Astex CEO)
  Person 2 von Emster, Kurt (Abingworth 201507– Managing Partner joined 201501 before venBio + MPM Capital + Franklin Templeton)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  City n. a. London
    Address record changed: 2021-02-04
     
Basic data Employees n. a.
  Currency USD
  Annual sales 315,000,000 (fund size at closing (2018) 2018-07-09)
     
    * Document for �About Section�: Abingworth LLP. (2/3/21). "Press Release: Abingworth Raises $465m for New Life Sciences Fund Abingworth Bioventures 8". London.
     
   
Record changed: 2021-02-04

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Abingworth (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top